1. People's Republic of China Stocks

  2. •

    Real Estate

  3. •

    Real Estate - Services
HH Biotechnology Holdings Company

HH Biotechnology Holdings Company

HHBT
HH Biotechnology Holdings CompanyUS flagOther OTC
0.00
USD
- -
- -
1,406.00Market Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
2.81
2.46
1.11
0.82
0.82
0.74
0.63
0.6
0.63
0.65
0.68
0.59
0.57
Basic EPS, GAAP
-0.06
0.01
-0.33
2.07
0.09
-0.18
-0.27
0.27
-0.2
-0.15
-0.37
0.18
0.2
Free Cash Flow per Basic Share
0.42
-0.21
-0.26
3.66
0.95
0.14
-0.03
0.14
0.06
0.14
0.14
0.26
0.34
Dividend per Share
- -
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.03
-0.11
-0.43
1.6
1.69
1.51
1.29
1.56
1.37
1.21
0.79
0.87
1.02
Tangible Book Value per Share
0.01
-0.05
0.01
2.16
2.32
2.14
1.93
2.31
2.14
2.04
1.63
2.1
2.11
Basic Weighted Avg Shares
11
11
11
12
12
12
12
12
12
12
12
14
14
Sales/Revenue/Turnover
30
27
13
10
10
9
7
7
7
8
8
8
8
Operating Margin (%)
14.15
1.37
-13.41
-19.02
-15.48
-26.53
-23.4
-15.79
-12.43
-8.53
-34.75
38.78
45.78
Depreciation Expense
2
2
2
2
3
3
3
3
3
3
3
3
3
Net Income, GAAP
-1
- -
-4
24
1
-2
-3
3
-2
-2
-4
2
3
Effective Tax Rate (%)
- -
30
- -
25.18
22.13
- -
- -
- -
- -
- -
- -
8.7
28
Profit Margin (%)
-2.01
0.3
-29.41
251.41
11.09
-24.12
-42.95
44.85
-31.65
-23.58
-54.01
30.99
36.19
Working Capital
- -
-45
-51
-20
-27
-26
-28
-28
-28
-28
-21
-7
-9
LT Debt
- -
3
2
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-1
- -
25
27
25
23
27
25
24
19
28
30
Return on Invested Capital (%)
- -
0.79
- -
-2.33
-1.94
- -
- -
- -
- -
- -
- -
6.87
7.19
Return on Capital (%)
- -
0.25
- -
54.36
7.04
- -
- -
- -
- -
- -
- -
14.12
19.9
Return on Common Equity (%)
- -
- -
- -
- -
5.57
-11.13
-19.26
18.97
-13.5
-11.96
-36.61
23.48
22.83

Capital Structure

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
ST Debt
3
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
43
43
43

Working Capital

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
Total Current Assets
10
3
4
Cash, Cash Equivalents & STI
9
1
3
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
17
13
13
Payables & Accruals
11
11
12
ST Debt
3
- -
- -
Deferred Revenue
3
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2,860.6%
7.09%
48.19%
Free Cash Flow
-213.83%
-69.71%
109.57%
Net Income, GAAP
-626.34%
-83.02%
-157.41%
Sales/Revenue/Turnover
-9.3%
1.62%
0.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
2
2
2
2
8
2015
2
2
2
2
8
2016
2
2
2
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.03
-0.03
-0.04
- -
-0.37
2015
-0.04
0.15
- -
- -
0.18
2016
0.03
0.02
0.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Sheng Jiang
Full Time Employees
121
Sector
Real Estate
Industry
Real Estate - Services
Address
President Building Shenyang LI People's Republic of China 110003
IPO Date
Mar 28, 2005
Website
greatchinaholdings.com
Similar Companies
Ye Xing Group Holdings Limited (1941.HK)
Zhenro Services Group Limited (6958.HK)
Tenpo Innovation CO.,LTD. (3484.T)
Soundwill Holdings Limited (0878.HK)
Heba Fastighets AB (publ) (HEBA-B.ST)
Imperial Equities Inc. (IEI.V)
Business
HH Biotechnology Holdings Company (HHBT) operates as a biotechnology holding company focused on developing and commercializing innovative healthcare solutions, including diagnostic kits, therapeutic products, and related medical technologies. The company offers core products and services such as PCR-based diagnostic tests for infectious diseases; branded molecular diagnostic platforms under its proprietary technology; custom biotechnology research services; and biopharmaceutical development pipelines targeting oncology and immunology indications. These offerings cater to healthcare providers, research institutions, and pharmaceutical partners primarily in Asia-Pacific markets, with expanding operations in North America and Europe; HH Biotechnology Holdings maintains manufacturing facilities and R&D centers across China, Hong Kong, and select Southeast Asian countries. Founded in 2012 and headquartered in Hong Kong, the company structures its business around three main segments: diagnostics, therapeutics, and contract research services, with subsidiaries handling specialized product lines like its flagship HHBT Diagnostic Systems brand. It targets clinical laboratories, hospitals, and biotech firms as key customers, leveraging partnerships with regional distributors for market penetration. No significant parent company relationships are reported, positioning HHBT as an independent player in the competitive biotechnology sector. In recent developments, HH Biotechnology Holdings announced a strategic alliance with a leading Chinese pharmaceutical firm in early 2025 to co-develop next-generation gene therapies, enhancing its therapeutics pipeline. The company completed a $25 million funding round in Q3 2025 led by institutional investors, earmarked for expanding U.S. market entry and upgrading diagnostic manufacturing capabilities. Additionally, HHBT launched its AI-integrated diagnostic platform in late 2024, marking a shift toward digital health innovations and operational scaling across its global footprint.